INTRODUCTION: An intronic germline mutation in the MSH2 gene, A-->T at nt942+3, interferes with the exon 5 donor splicing mechanism leading to a mRNA lacking exon 5. This mutation causes typical hereditary non-polyposis colorectal cancer (HNPCC) and has been observed in numerous probands and families world wide. Recurrent mutations either arise repeatedly de novo or emanate from ancestral founding mutational events. The A-->T mutation had previously been shown to be enriched in the population of Newfoundland where most families shared a founder mutation. In contrast, in England, haplotypes failed to suggest a founder effect. If the absence of a founder effect could be proven world wide, the frequent de novo occurrence of the mutation would constitute an unexplored predisposition. METHODS: We studied 10 families from England, Italy, Hong Kong, and Japan with a battery of intragenic and flanking polymorphic single nucleotide and microsatellite markers. RESULTS: Haplotype sharing was not apparent, even within the European and Asian kindreds. Our marker panel was sufficient to detect a major mutation arising within the past several thousand generations. DISCUSSION: As a more ancient founder is implausible, we conclude that the A-->T mutation at nt942+3 of MSH2 occurs de novo with a relatively high frequency. We hypothesise that it arises as a consequence of misalignment at replication or recombination caused by a repeat of 26 adenines, of which the mutated A is the first. It is by far the most common recurrent de novo germline mutation yet to be detected in a human mismatch repair gene, accounting for 11% of all known pathogenic MSH2 mutations.
INTRODUCTION: An intronic germline mutation in the MSH2 gene, A-->T at nt942+3, interferes with the exon 5 donor splicing mechanism leading to a mRNA lacking exon 5. This mutation causes typical hereditary non-polyposis colorectal cancer (HNPCC) and has been observed in numerous probands and families world wide. Recurrent mutations either arise repeatedly de novo or emanate from ancestral founding mutational events. The A-->T mutation had previously been shown to be enriched in the population of Newfoundland where most families shared a founder mutation. In contrast, in England, haplotypes failed to suggest a founder effect. If the absence of a founder effect could be proven world wide, the frequent de novo occurrence of the mutation would constitute an unexplored predisposition. METHODS: We studied 10 families from England, Italy, Hong Kong, and Japan with a battery of intragenic and flanking polymorphic single nucleotide and microsatellite markers. RESULTS: Haplotype sharing was not apparent, even within the European and Asian kindreds. Our marker panel was sufficient to detect a major mutation arising within the past several thousand generations. DISCUSSION: As a more ancient founder is implausible, we conclude that the A-->T mutation at nt942+3 of MSH2 occurs de novo with a relatively high frequency. We hypothesise that it arises as a consequence of misalignment at replication or recombination caused by a repeat of 26 adenines, of which the mutated A is the first. It is by far the most common recurrent de novo germline mutation yet to be detected in a human mismatch repair gene, accounting for 11% of all known pathogenic MSH2 mutations.
Authors: P Peltomäki; L A Aaltonen; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; J S Green; J R Jass; J L Weber; F S Leach Journal: Science Date: 1993-05-07 Impact factor: 47.728
Authors: N Morral; J Bertranpetit; X Estivill; V Nunes; T Casals; J Giménez; A Reis; R Varon-Mateeva; M Macek; L Kalaydjieva Journal: Nat Genet Date: 1994-06 Impact factor: 38.330
Authors: B Liu; R E Parsons; S R Hamilton; G M Petersen; H T Lynch; P Watson; S Markowitz; J K Willson; J Green; A de la Chapelle Journal: Cancer Res Date: 1994-09-01 Impact factor: 12.701
Authors: P Fidalgo; M R Almeida; S West; C Gaspar; L Maia; J Wijnen; C Albuquerque; A Curtis; M Cravo; R Fodde; C N Leitao; J Burn Journal: Eur J Hum Genet Date: 2000-01 Impact factor: 4.246
Authors: F S Leach; N C Nicolaides; N Papadopoulos; B Liu; J Jen; R Parsons; P Peltomäki; P Sistonen; L A Aaltonen; M Nyström-Lahti Journal: Cell Date: 1993-12-17 Impact factor: 41.582
Authors: Aung Ko Win; Mark A Jenkins; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Graham G Giles; Jack Goldblatt; Barbara A Leggett; John L Hopper; Stephen N Thibodeau; Noralane M Lindor Journal: J Med Genet Date: 2011-06-02 Impact factor: 6.318
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Jerneja Tomsic; Sandya Liyanarachchi; Heather Hampel; Monika Morak; Brittany C Thomas; Victoria M Raymond; Anu Chittenden; Hans K Schackert; Stephen B Gruber; Sapna Syngal; Alessandra Viel; Elke Holinski-Feder; Stephen N Thibodeau; Albert de la Chapelle Journal: Int J Cancer Date: 2011-08-30 Impact factor: 7.396
Authors: Mef Nilbert; Friedrik P Wikman; Thomas V O Hansen; Henrik B Krarup; Torben F Orntoft; Finn C Nielsen; Lone Sunde; Anne-Marie Gerdes; Dorthe Cruger; Susanne Timshel; Marie-Louise Bisgaard; Inge Bernstein; Henrik Okkels Journal: Fam Cancer Date: 2008-06-20 Impact factor: 2.375
Authors: Daniel S Falster; Sigve Nakken; Marie Bergem-Ohr; Einar Andreas Rødland; Jarle Breivik Journal: J Mol Evol Date: 2010-03-06 Impact factor: 2.395